BAFF is a marker of hypogammaglobulinemia, neuroaxonal damage and inflammation in multiple sclerosis patients on ocrelizumab.

J Neuroinflammation · 2025 · PMC12765282 · PMID 41310706

Europe PMC DOI

hedged sentences

0.0400

closest p · 0.8× alpha

0.0720

boldest claim

The sentences

showed a trendp = 0.04actually significant

2 B) and showed a trend ( R = −0.29, p = 0.04) with treatment duration (i.e. months on ocrelizumab prior to sampling; Fig. 2 C).

also in 31,039 other papers

did not reach statistical significancep = 0.072so close (0.05 < p ≤ 0.1)

While on initial analysis CXCL9 showed significant correlation, when accounting for age the correlation did not reach statistical significance ( R = 0.26, p = 0.072).

also in 61,332 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.